Acute safety and pharmacokinetics of intravenous busulfan when used with oval busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I study

The unpredictable intestinal absorption and erratic bioavailability of oral busulfan (Bu) has limited the drug's use in high-dose pretransplantation c onditioning therapy To standardize drug delivery; we solubilized Bu for par enteral use. This new intravenous (IV) Bu formulation was combined with ora l Bu and cyclophosphamide (Cy) to evaluate (1) the human acute toxicity of IV Bu and its solvent system and (2) the pharmacokinetics of Bu in patients undergoing hematopoietic progenitor cell transplantation (HPCT). One dose of IV Bu (escalating from 0.08 to 0.8 mg/kg) was given over 2 hours by pump ; 6 hours later, an oral Bu regimen was begun, consisting of 1 mg/kg every 6 hours for 15 doses, followed by Cy 60 mg/kg daily for 2 days. After I day of rest, HPCT was performed. The TV Bu dose was well tolerated and did not produce any acute toxicity reaction that could be attributed to the solven t system of dimethylacetamide and polyethylene glycol (PEG)-400. All observ ed treatment-related toxicity was as would be expected after high-dose oral Bu plus Cy When the IV Bu was used as reference solution, the pharmacokine tic analysis indicated an average bioavailability of oral high-dose Bu of 6 9%, ranging from <10% to virtually 100%. Further, the 2-hour infusion of IV Bu gave a time to maximum plasma concentration following drug administrati on similar to that of oral Bu (2 hours and 1.8 hours, respectively), and TV Bu had a clearance similar to that of oral Bu. Based on the data in this s tudy we suggest that the optimal (starting) dose of IV Bu (in combination w ith Cy) in our forthcoming phase 2 trial should be on the order of 0.8 mg/k g to target an area under the curve (AUC) of 1100 to 1200 <mu>mol/L per min ute. This mould secure myeloablation and engraftment but save the vast majo rity of patients from the increased risk of serious hepatic veno-occlusive disease that has been reported when the AUC le cel exceeds 1500 mu mol/L pe r minute. Bu administration via the IV route will assure complete bioavaila bility and reliable systemic drug exposure with more predictable blood leve ls and, therefore, possibly lower the risks for serious/life-threatening to xicity, graft rejection, and recurrent leukemia.